|
|
 |
|
Viewing report
|
|
|
|
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?
MP Advisors, June 2011, Pages: 51
An estimated 270m to 300m people are infected with Hepatitis C Virus (HCV) worldwide, with about 2.5m to 4.5m pts in the US alone. Recently launched Protease Inhibitors’ Incivek (Vertex/JNJ/Mitsubishi) and Victrelis (Merck/SGP) when added to the old Standard of Care PEGylated- Interferon alpha and Ribavirin have benefited the HCV infected patients - but limitations and unmet need persist.
Major pharmas and research focused companies continue to develop better alternatives. This report is an in-depth analysis of the evolving market. This report looks at the complexities of the disease, the heterogeneity of the patient population and the innovative drugs in the pipeline to fill the gap. More exciting treatment options are on the cards which could bring a major shift in the treatment paradigm for Hepatitis C Viral Infection.
Key Topics Covered Include:
- HCV-Market Overview
- Current and Future Leaders
- Unmet Needs
- Pipeline and Drug Analysis
- NS3- Protease Inhibitors
- NS5B- Polymerase Inhibitors
- NS5A Inhibitors
- Interferon’s
- Interferon Free Combination – An All Oral Option
- Disease Overview and Etiology
- Genotypes 1, 2, 3, 4
- Clinical Trial Design
- Pipeline Failures
- Market Forecasts to 2017
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
